Aug 1, 2022 07:00AM
Jul 28, 2022 01:02PM
Jul 27, 2022 09:07AM
Jul 27, 2022 07:39AM
Jul 27, 2022 07:14AM
Jul 27, 2022 07:00AM
Jun 28, 2022 04:01PM ObsEva SA (OBSV) Announces UK Marketing Authorization for Yselty
Jun 28, 2022 04:01PM
Jun 17, 2022 07:00AM
May 25, 2022 07:01AM
May 25, 2022 07:00AM
May 19, 2022 07:06AM
May 19, 2022 07:05AM
May 17, 2022 07:00AM ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 05:45AM
May 9, 2022 07:04AM
May 9, 2022 07:00AM
May 2, 2022 07:03AM
May 2, 2022 07:00AM
Apr 25, 2022 07:05AM
Apr 25, 2022 07:00AM ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Apr 25, 2022 05:30AM
Mar 10, 2022 07:00AM
Mar 10, 2022 01:00AM
Feb 10, 2022 04:14PM
Feb 10, 2022 04:11PM
Feb 4, 2022 04:16PM
Feb 4, 2022 04:15PM ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Feb 1, 2022 07:02AM
Feb 1, 2022 07:00AM
Jan 6, 2022 07:04AM
Jan 6, 2022 07:00AM
Dec 17, 2021 07:00AM
Dec 13, 2021 04:52AM
Dec 13, 2021 01:00AM ObsEva Appoints Will Brown as Chief Financial Officer
Dec 13, 2021 01:00AM
Dec 10, 2021 01:00AM
Dec 2, 2021 01:00AM
Nov 22, 2021 05:46AM
Nov 22, 2021 01:05AM
Nov 4, 2021 05:44AM
Nov 4, 2021 02:00AM ObsEva Announces Third Quarter 2021 Financial Results and Business Update
Oct 20, 2021 05:48AM
Oct 20, 2021 01:00AM
Oct 19, 2021 01:00AM
Oct 13, 2021 01:00AM
Sep 30, 2021 01:00AM
Sep 30, 2021 01:00AM
Sep 15, 2021 06:15AM ObsEva SA (OBSV) Submits NDA to US FDA for Linzagolix for the Treatment of Uterine Fibroids
Sep 15, 2021 01:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All